Inhalation Sciences (ISAB) has announced that “a leading European inhaled pharmaceutical developer” has contracted with the company for a feasibility study using ISAB’s PreciseInhale aerosol generator with new nebulizer capabilities. The feasibility study is the first to use the nebulizer feature for the PreciseInhale system, which launched in February 2019, the company said. According to ISAB, the study was initiated in June 2019 and is expected to run through October 2019.
ISAB CEO Lena Heffler commented, “Few tests are more crucial in an inhaled drug’s lifetime than pre-clinical feasibility studies. With a typical drug costing on average 2.6 BUSD to develop, being able to minimize errors and generate predictive data early on saves huge costs. And means faster drug development. The choice of PreciseInhale confirms its unique capabilities. We know the client faced challenges with this material earlier on. Our ability to generate predictive data even from tiny amounts of challenging substance only available in solution was key. We’re delighted they chose our system.”
Read the Inhalation Sciences press release.
